𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Applications of Site-Targeted Perfluorocarbon Nanoparticles in Diagnosis and Therapy of Atherosclerotic Disease

✍ Scribed by S.D. Caruthers


Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
106 KB
Volume
2
Category
Article
ISSN
1549-9634

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Molecular imaging of angiogenic therapy
✍ Patrick M. Winter; Shelton D. Caruthers; John S. Allen; Kejia Cai; Todd A. Willi πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 313 KB

## Abstract Noninvasive molecular imaging of angiogenesis could play a critical role in the clinical management of peripheral vascular disease patients. The Ξ±~Ξ½~Ξ²~3~‐integrin, a well‐established biomarker of neovascular proliferation, is an ideal target for molecular imaging of angiogenesis. This s

Metabolic networks for assessment of the
✍ Shigeki Hirano; Thomas Eckert; Toni Flanagan; David Eidelberg πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 245 KB πŸ‘ 1 views

## Abstract Neuroimaging and modern computational techniques like spatial covariance analysis have contributed greatly to the understanding of neural system abnormalities in neurodegenerative disorders such as Parkinson's disease (PD). The application of network analysis to metabolic PET data obtai

The application of nanoparticles in gene
✍ Fernando Herranz; Elena Almarza; Ignacio RodrΓ­guez; Beatriz Salinas; Yamilka Ros πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 819 KB

## Abstract The combination of nanoparticles, gene therapy, and medical imaging has given rise to a new field known as gene theranostics, in which a nanobioconjugate is used to diagnose and treat the disease. The process generally involves binding between a vector carrying the genetic information a

Targeted therapy in head and neck cancer
✍ Corey J. Langer πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 174 KB πŸ‘ 2 views

## Abstract In patients with squamous cell carcinoma of the head and neck (SCCHN), tumor recurrence, secondary tumors, and comorbidities contribute to therapy failure, and treatment approaches often are limited by their toxicity. With the incorporation of targeted therapies, the number of options a